Update on the management of febrile neutropenia in hematologic patients
F Escrihuela-Vidal, J Laporte, A Albasanz-Puig, C Gudiol, F Escrihuela-Vidal, J Laporte, A Albasanz-Puig, C Gudiol
Abstract
Febrile neutropenia is a common complication in patients with hematologic malignancies receiving chemotherapy, and is associated with high morbidity and mortality. Infections caused by multidrug-resistant bacteria represent a therapeutic challenge in this high-risk patient population, since inadequate initial empirical antibiotic treatment can seriously compromise prognosis. Besides, reducing antimicrobial exposure is a cornerstone in the fight against resistance.
References
- Gudiol C, Aguilar-Guisado M, Azanza JR, Candel FJ, Cantón R, Carratalà J, et al. . Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. Enferm Infecc Microbiol Clin. 2019. March 26 pii: . doi: 10.1016/j.eimc.2019.01.013
- Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cor-donnier C, et al. . Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014; 68(4):321-31. doi: 10.1016/j.jinf.2013.12.006.
- Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, et al. . Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem re-sistance in a multicentre prospective survey. Am J Hematol 2016; 91(11):1076-1081. doi: 10.1002/ajh.24489
- Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Ce-brecos C, Falantes J. Optimisation of empirical antimicrobial ther-apy in patients with haematological malignancies and febrile neu-tropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017; 4:e573-e583. doi: 10.1016/S2352-3026(17)30211-9
- Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. . Ef-fect of piperacillin-tazobactam vs meropenem on 30-day mortal-ity for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 2018; 320(10): 984-994. doi: 10.1001/jama.2018.12163.
- Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maes-tro-de la Calle G, et al. . Efficacy of β-lactam/ β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-β-lactamase-producing Enterobacteriaceae in hematological patients with neutropenia. Antimicrob Agents Chemother 2017; 61(8): e00164-17. doi: 10.1128/AAC.00164-17.
- Ram R, Halavy Y, Amit O, Paran Y, Katchman E, Yachini B, et al. . Extended vs bolus infusion of broad-spectrum β-lactams for fe-brile neutropenia: an unblinded, randomized trial. Clin Infect Dis 2018; 67(8):1153-1160. doi: 10.1093/cid/ciy258.
- Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. . Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guide-line update. J Clin Oncol 2018; 36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211.
- Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. . The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.” J Clin Oncol 2000; 18(16): 3038-3051. Doi: 10.1200/JCO.2000.18.16.3038
Source: PubMed